RBC Capital analyst Leonid Timashev initiated coverage of Revolution Medicines (RVMD) with an Outperform rating and $77 price target The firm believes Revolution is best positioned to execute on targeting RAS across oncology, given its “impressive” efficacy data, development lead, and pipeline. RBC thinks the company’s Phase III readout in 2026 is “highly likely to hit.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Promising Oncology Leader with Strategic Advancements and Competitive Edge
- Revolution Medicines Advances RAS(ON) Inhibitor Study in Gastrointestinal Cancers
- Revolution Medicines Advances RAS(ON) Inhibitors in NSCLC Study
- Revolution Medicines’ RASolve 301 Study: A Potential Game-Changer for NSCLC Treatment
- Revolution Medicines Advances Phase 3 Trial for Pancreatic Cancer Treatment